pain

News

A phase 3 trial of Vertanical's cannabis extract in back pain has been published, and the results bode well for marketing applications under review.

News

Tonix Pharma is preparing to launch a new therapy for fibromyalgia that analysts predict could make hundreds of millions of dollars in annual sales.

News

Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.

News

The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.

News

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

News

A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.